Go offline with the Player FM app!
Top 8: The Single Arm Studies and What are the Alternatives?
Manage episode 506628118 series 2400265
Why You Should Listen:
f you’ve ever wondered whether single-arm studies are “good enough” for regulators or HTA bodies, this episode will challenge your assumptions. Anja Schiel, one of Europe’s leading voices at the regulator–HTA interface, explains why comparisons matter, where single-arm designs break down, and what smarter alternatives exist.
You’ll walk away with:
✔ A clearer understanding of the limits of single-arm trials
✔ Practical strategies for choosing comparators that strengthen your evidence package
✔ Insight into adaptive and hybrid designs that balance efficiency with rigor
✔ A regulator/HTA insider’s perspective on what decision-makers really need from statisticians
Episode Highlights:
00:01:36 – Meet Anja Schiel and learn how she bridges regulation and HTA
00:02:28 – Why connecting regulators and HTA bodies early matters for drug development
00:06:07 – Where single-arm studies often fall short in real-world decision-making
00:08:01 – What accelerated approvals have taught us about assumptions in trial design
00:10:17 – Why comparison—not just randomization—is at the heart of sound evidence
00:12:12 – The pitfalls of relying on literature-based or naïve comparisons
00:16:54 – How regulators and HTA approach evidence differently
00:17:00 – What “concurrent control” really means and why it’s crucial
00:20:33 – Strategic thinking when selecting comparators for long-term value
00:26:00 – The role of adaptive and hybrid designs in modern trials
00:33:59 – Ethical considerations when trial designs fall short
00:36:26 – Why rare diseases demand smarter collaboration and evidence planning
00:40:25 – Communicating study objectives and estimands clearly for all stakeholders
00:44:55 – Final takeaways: how statisticians can lead the push for better designs
Links:
🔗 The Effective Statistician Academy – I offer free and premium resources to help you become a more effective statistician.
🔗 Medical Data Leaders Community – Join my network of statisticians and data leaders to enhance your influencing skills.
🔗 My New Book: How to Be an Effective Statistician - Volume 1 – It’s packed with insights to help statisticians, data scientists, and quantitative professionals excel as leaders, collaborators, and change-makers in healthcare and medicine.
🔗 PSI (Statistical Community in Healthcare) – Access webinars, training, and networking opportunities.
Join the Conversation:
Did you find this episode helpful? Share it with your colleagues and let me know your thoughts! Connect with me on LinkedIn and be part of the discussion.
Subscribe & Stay Updated:
Never miss an episode! Subscribe to The Effective Statistician on your favorite podcast platform and continue growing your influence as a statistician.


461 episodes
Manage episode 506628118 series 2400265
Why You Should Listen:
f you’ve ever wondered whether single-arm studies are “good enough” for regulators or HTA bodies, this episode will challenge your assumptions. Anja Schiel, one of Europe’s leading voices at the regulator–HTA interface, explains why comparisons matter, where single-arm designs break down, and what smarter alternatives exist.
You’ll walk away with:
✔ A clearer understanding of the limits of single-arm trials
✔ Practical strategies for choosing comparators that strengthen your evidence package
✔ Insight into adaptive and hybrid designs that balance efficiency with rigor
✔ A regulator/HTA insider’s perspective on what decision-makers really need from statisticians
Episode Highlights:
00:01:36 – Meet Anja Schiel and learn how she bridges regulation and HTA
00:02:28 – Why connecting regulators and HTA bodies early matters for drug development
00:06:07 – Where single-arm studies often fall short in real-world decision-making
00:08:01 – What accelerated approvals have taught us about assumptions in trial design
00:10:17 – Why comparison—not just randomization—is at the heart of sound evidence
00:12:12 – The pitfalls of relying on literature-based or naïve comparisons
00:16:54 – How regulators and HTA approach evidence differently
00:17:00 – What “concurrent control” really means and why it’s crucial
00:20:33 – Strategic thinking when selecting comparators for long-term value
00:26:00 – The role of adaptive and hybrid designs in modern trials
00:33:59 – Ethical considerations when trial designs fall short
00:36:26 – Why rare diseases demand smarter collaboration and evidence planning
00:40:25 – Communicating study objectives and estimands clearly for all stakeholders
00:44:55 – Final takeaways: how statisticians can lead the push for better designs
Links:
🔗 The Effective Statistician Academy – I offer free and premium resources to help you become a more effective statistician.
🔗 Medical Data Leaders Community – Join my network of statisticians and data leaders to enhance your influencing skills.
🔗 My New Book: How to Be an Effective Statistician - Volume 1 – It’s packed with insights to help statisticians, data scientists, and quantitative professionals excel as leaders, collaborators, and change-makers in healthcare and medicine.
🔗 PSI (Statistical Community in Healthcare) – Access webinars, training, and networking opportunities.
Join the Conversation:
Did you find this episode helpful? Share it with your colleagues and let me know your thoughts! Connect with me on LinkedIn and be part of the discussion.
Subscribe & Stay Updated:
Never miss an episode! Subscribe to The Effective Statistician on your favorite podcast platform and continue growing your influence as a statistician.


461 episodes
All episodes
×Welcome to Player FM!
Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.